GxP Lifeline Pharmaceutical Publication Click to visit GxP Lifeline Home Click to visit mastercontrol.com

Featured Articles

January 2012

Gerhard NeurauterOlaf Schoepke

The New Life Science Solution and its Implications on Document Management for Pharmaceutical Companies

by Dr. Gerhard Neurauter and Dr. Olaf Schoepke

The European Medicines Agency (EMA) recently announced a new pharmacovigilance legislation, describing how to modernize its pharmacovigilance system, how to improve patient safety and how to supply health information to patients. Considering the consequences on information management and business process, pharmaceutical companies have a very short timeline in which to adapt to and implement the initial phase. The attempt to define and establish the "Identification of Medicinal Product (IDMP)" standard as a global harmonized electronic exchange format seems to be the biggest change in the regulatory registration process today. How agencies and pharmaceutical companies can address this new legislation along with the respective consequences for their data management is described in this article.

Read more.

Holly Scott

What to Expect When They're Inspecting - Part II

by Holly Scott
Biologics Consulting Group, Senior Consultant and Former CBER Consumer Safety Officer and FDA Field Investigator

The first segment of this series focused on some of the non-traditional variables that can have an effect on any FDA inspection and how to achieve a positive outcome regardless of the inspectional conclusion. That article generated some blog discussion on FDA's objectivity. I wanted to clarify some of those issues. FDA investigators are trained to be objective in all situations and will approach their inspection in this manner. However, firm management needs to understand that when intentional barriers to an effective inspection are presented or the FDA Investigator is met with a less-than-cooperative attitude, the realistic conclusion is that management is trying to hide objectionable GMP conditions, leaving the Investigator no choice but to be even more thorough to ensure there are no safety or quality risks to the consumer. It isn't that an FDA Investigator is showing bias or being subjective, they're "Investigators" - it's their job to do so.

Read more

Martin Browning

Annex 11: The EU's New Expectations for Regulated Computerized Systems

by Martin Browning
President and Co-Founder, EduQuest

In 2011, the European Union (EU) revised its guidance for the life cycle of computerized systems to reflect the increased use and complexity of automated systems in the pharmaceutical industry. The guidance, called Annex 11, also was revised in response to an alarming number of problems detected in computerized systems.

Annex 11 is one of several guidance documents that supplement the EU's GMP rules (EUDRALEX Rules Governing Medicinal Products in the European Union, Volume 4, Good Manufacturing Practice). It applies to all human and veterinary medicinal products made or sold in the EU.

Read more


Featured Webinar:

Featured White Paper:

Previous Newsletters:

Watch Customer Videos

View Upcoming Events

Did You Know?

Cphl Japan
March 21-23, 2012, Tokyo, Japan

April 17-20, 2012, Munich, Germany

SQA Annual Meeting
April 24-26, 2012, Miami, FL

May 1-3, 2012, New York, NY

May 21-23, 2012, Anaheim, CA

View More Events

Did you know that one of the most costly areas of business for any pharmaceutical or biotechnology company has always been clinical research? Now more than ever the cost of bringing a product to market is staggering and as patents on trademark products expire the hope for recovering costs of research get smaller and smaller.
Read More